Corcept Therapeutics to Announce Fourth Quarter and Full-year 2021 Financial Results, Provide Corporate Update and Host Conference Call

Rhea-AI Summary

Corcept Therapeutics (CORT) will report its fourth quarter and full-year 2021 financial results on February 15, 2022, followed by a corporate update. A conference call will be held that day at 5:00 p.m. ET.

The company has developed proprietary compounds to modulate cortisol effects and is conducting clinical trials for several serious disorders, including Cushing’s syndrome, ovarian cancer, and more. Korlym®, its FDA-approved medication for Cushing’s syndrome, highlights its market presence.

Positive

• Conducting clinical trials for various serious disorders, indicating growth potential.
• Korlym® approved for Cushing’s syndrome, showcasing successful product development.

Negative

• None.

MENLO PARK, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full-year 2021 financial results and provide a corporate update on February 15, 2022. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).

Conference Call Information
To participate, click the link below and enter your information. The link will become active 15 minutes prior to the scheduled start time.

Click to Join Meeting

Alternatively, you may dial 1-833-693-0540 from the United States or 1-661-407-1581 internationally approximately 15 minutes before the start of the call. The passcode will be 1861918.

A replay will be available through February 22, 2022, at 1-855-859-2056 from the United States and 1-404-537-3406 internationally. The passcode will be 1861918. You may also access a replay on the Investors / Past Events tab of www.corcept.com

About Corcept Therapeutics

Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. The company is conducting clinical trials of its leading cortisol modulators as potential treatments for patients with Cushing’s syndrome, ovarian cancer, castration-resistant prostate cancer, weight gain caused by the use of antipsychotic medications and liver disease. Corcept’s approved medication, Korlym®, was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing’s syndrome.

CONTACT:
Corcept Therapeutics
Investor Relations
ir@corcept.com
www.corcept.com

FAQ

When will Corcept Therapeutics report its financial results?

Corcept Therapeutics will report its financial results on February 15, 2022.

What is the ticker symbol for Corcept Therapeutics?

The ticker symbol for Corcept Therapeutics is CORT.

What disorders is Corcept Therapeutics focusing on in its clinical trials?

Corcept is focusing on disorders like Cushing’s syndrome, ovarian cancer, and more in its clinical trials.

What time is the conference call for Corcept's financial results?

The conference call for Corcept's financial results is scheduled for 5:00 p.m. Eastern Time on February 15, 2022.

How can I participate in the Corcept Therapeutics conference call?

You can participate by clicking a link that will be active 15 minutes before the call or by dialing in at the provided numbers.